The estimated Net Worth of Matthew R. Henn is at least $3.41 Million dollars as of 15 August 2024. Matthew Henn owns over 2,813 units of Seres Therapeutics Inc stock worth over $71,579 and over the last 5 years he sold MCRB stock worth over $2,482,596. In addition, he makes $859,452 as Executive Vice President and Chief Scientific Officer at Seres Therapeutics Inc.
Matthew has made over 6 trades of the Seres Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 2,813 units of MCRB stock worth $2,954 on 15 August 2024.
The largest trade he's ever made was selling 91,812 units of Seres Therapeutics Inc stock on 1 December 2020 worth over $2,482,596. On average, Matthew trades about 9,908 units every 128 days since 2020. As of 15 August 2024 he still owns at least 68,170 units of Seres Therapeutics Inc stock.
You can see the complete history of Matthew Henn stock trades at the bottom of the page.
Dr. Matthew R. Henn Ph.D. serves as Executive Vice President, Chief Scientific Officer of the Company. Since joining our company at its launch in June 2012, he has held positions of increasing seniority, most recently as Executive Vice President, Head of Discovery and Microbiome R&D from January 2018 to February 2019, and previously as Senior Vice President, Head of Discovery and Bioinformatics from June 2012 to January 2018. Prior to joining our company, he was the Director of Viral Genomics and Assistant Director of the Genome Sequencing Center for Infectious Diseases at the Broad Institute of MIT and Harvard. He currently serves on the scientific advisory boards of the Forsyth Institute and Growcentia, Inc., an agricultural microbiome company. Dr. Henn earned his B.S. in Ecology and Evolutionary Sciences from the University of New Hampshire and his Ph.D. in Ecosystem Sciences from the University of California at Berkeley, where he was a NASA Earth Systems Sciences Fellow, and trained as a NSF Postdoctoral Fellow in Microbiology at Duke University.
As the Executive Vice President and Chief Scientific Officer of Seres Therapeutics Inc, the total compensation of Matthew Henn at Seres Therapeutics Inc is $859,452. There are 3 executives at Seres Therapeutics Inc getting paid more, with Eric Shaff having the highest compensation of $2,032,550.
Matthew Henn is 45, he's been the Executive Vice President and Chief Scientific Officer of Seres Therapeutics Inc since 2019. There are 18 older and 1 younger executives at Seres Therapeutics Inc. The oldest executive at Seres Therapeutics Inc is Dennis Ausiello, 74, who is the Independent Director.
Matthew's mailing address filed with the SEC is C/O SERES THERAPEUTICS, INC., 101 CAMBRIDGE PARK DRIVE, CAMBRIDGE, MA, 02140.
Over the last 9 years, insiders at Seres Therapeutics Inc have traded over $37,132,594 worth of Seres Therapeutics Inc stock and bought 17,627,131 units worth $47,525,463 . The most active insiders traders include Noubar Afeyan, Health Ltp Fund General Par..., and Health Science Us Holdings,.... On average, Seres Therapeutics Inc executives and independent directors trade stock every 35 days with the average trade being worth of $251,393. The most recent stock trade was executed by Thomas Des Rosier on 15 August 2024, trading 2,656 units of MCRB stock currently worth $2,789.
seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.
Seres Therapeutics Inc executives and other stock owners filed with the SEC include: